Dose-dense therapy improves survival in aggressive non-Hodgkin’s lymphoma.

Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R.

http://www.ncbi.nlm.nih.gov/pubmed/19693500